
|Articles|April 22, 2011
Increased Demand Causes Fuji to Expand Astaxanthin Production
The plan is to double current production capacity.
Advertisement
Fuji Chemical Industry Company, Ltd., (Toyama, Japan) announced plans to double production of its AstaReal natural astaxanthin (Haematococcus pluavialis) in response to increased demand worldwide, the company says. Production will ramp up at Fuji’s wholly owned subsidiary BioReal AB in Gustavsberg, Sweden.
The company says demand has been driven by increasing science supporting AstaReal’s “positive effects on health,” along with AstaReal’s GRAS approval in the United States last year.
The company says that production at the BioReal facility can be expanded rapidly. The plan is to double current production capacity.
Advertisement
Advertisement
Advertisement
Trending on Nutritional Outlook - Supplement, Food & Beverage Manufacturing Trends
1
FEMA GRAS Recognition Expands Regulatory Pathway for Layn Natural Ingredients’ Stevia Sweetener
2
Nutrition Requirements in Medical Training Are Expanding: Here's What the Industry Should Know
3
High-Dose Ashwagandha Root Extract Demonstrates Safety and Tolerability in Clinical Trial
4
Satiety Benefits Extend Beyond Weight Management to Support Metabolic Health
5





